PE20020055A1 - STABLE LIQUID AND SOLID FORMULATIONS INCLUDING A NON-SEDATING ANTIHISTAMINE AND A NASAL DECONGESTANT - Google Patents
STABLE LIQUID AND SOLID FORMULATIONS INCLUDING A NON-SEDATING ANTIHISTAMINE AND A NASAL DECONGESTANTInfo
- Publication number
- PE20020055A1 PE20020055A1 PE2001000462A PE2001000462A PE20020055A1 PE 20020055 A1 PE20020055 A1 PE 20020055A1 PE 2001000462 A PE2001000462 A PE 2001000462A PE 2001000462 A PE2001000462 A PE 2001000462A PE 20020055 A1 PE20020055 A1 PE 20020055A1
- Authority
- PE
- Peru
- Prior art keywords
- nasal decongestant
- stable liquid
- solid formulations
- formulations including
- sedating antihistamine
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000000133 nasal decongestant Substances 0.000 title abstract 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 title 1
- 230000001387 anti-histamine Effects 0.000 title 1
- 239000000739 antihistaminic agent Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- 235000003599 food sweetener Nutrition 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000003765 sweetening agent Substances 0.000 abstract 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 abstract 1
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 abstract 1
- 229960005174 ambroxol Drugs 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003172 expectorant agent Substances 0.000 abstract 1
- 230000003419 expectorant effect Effects 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 abstract 1
- 229960003088 loratadine Drugs 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 abstract 1
- 229960003908 pseudoephedrine Drugs 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a) DE 0,4mg/ml A 0,7mg/ml DE LORATADINA; b) UN DESCONGESTIONANTE NASAL TAL COMO PSEUDOEFEDRINA, PROPANOLAMINA ; c) UN EXPECTORANTE TAL COMO AMBROXOL Y d) UN VEHICULO FARMACEUTICAMENTE ACEPTABLE. LA COMPOSICION CONTIENE ADEMAS UN AGENTE ANTIMICROBIANO, EDULCORANTE, PROPILENGLICOL Y GLICERINA. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA ESTABLE EN FORMA LIQUIDA QUE COMPRENDE UNA COMBINACION DE: a) UN EDULCORANTE TAL COMO SORBITOL, SACARIDO DE SODIO; b) UN VEHICULO LIQUIDO Y c) UN SISTEMA BUFFER PARA MANTENER EL pH EN EL RANGO DE 3 A 5. LA COMPOSICION ES ESTABLE A LA CONTAMINACION DE MICROORGANISMOS DURANTE PERIODOS DE 4 MESES A 36 MESES A TEMPERATURA AMBIENTEIT REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES: a) FROM 0.4mg / ml TO 0.7mg / ml OF LORATADINE; b) A NASAL DECONGESTANT SUCH AS PSEUDOEPHEDRINE, PROPANOLAMINE; c) AN EXPECTORANT SUCH AS AMBROXOL AND d) A PHARMACEUTICALLY ACCEPTABLE VEHICLE. THE COMPOSITION ALSO CONTAINS AN ANTIMICROBIAL AGENT, SWEETENER, PROPYLENE GLYCOL AND GLYCERIN. IT ALSO REFERS TO A STABLE PHARMACEUTICAL COMPOSITION IN LIQUID FORM INCLUDING A COMBINATION OF: a) A SWEETENER SUCH AS SORBITOL, SODIUM SACRED; b) A LIQUID VEHICLE AND c) A BUFFER SYSTEM TO MAINTAIN THE pH IN THE RANGE OF 3 TO 5. THE COMPOSITION IS STABLE TO THE CONTAMINATION OF MICROORGANISMS DURING PERIODS OF 4 MONTHS TO 36 MONTHS AT ROOM TEMPERATURE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MXPA/A/2000/005129A MXPA00005129A (en) | 2000-05-24 | Liquid and stable antihistaminic - anti-congestive pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020055A1 true PE20020055A1 (en) | 2002-02-12 |
Family
ID=33308448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000462A PE20020055A1 (en) | 2000-05-25 | 2001-05-22 | STABLE LIQUID AND SOLID FORMULATIONS INCLUDING A NON-SEDATING ANTIHISTAMINE AND A NASAL DECONGESTANT |
Country Status (7)
| Country | Link |
|---|---|
| AU (1) | AU2001264806A1 (en) |
| BR (1) | BR0111018A (en) |
| CR (1) | CR6804A (en) |
| EC (1) | ECSP024356A (en) |
| PA (1) | PA8517201A1 (en) |
| PE (1) | PE20020055A1 (en) |
| WO (1) | WO2001089527A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6635654B1 (en) | 2003-01-09 | 2003-10-21 | Allergan, Inc. | Ophthalmic compositions containing loratadine |
| CA2612179C (en) | 2005-06-17 | 2016-08-02 | Aft Pharmaceuticals Limited | A pharmaceutical composition comprising loratadine and its use to treat patients with upper respiratory mucosal congestion |
| AR061668A1 (en) * | 2006-06-29 | 2008-09-10 | Schering Corp | ANTIHISTAMINIC SYRINGES, STABLE TO STORAGE, WITHOUT SUGAR |
| EP4281180A4 (en) * | 2021-01-22 | 2024-12-18 | Model Medicines, Inc. | SARS-COV-2 THERAPEUTICS |
| CN116898799B (en) * | 2023-08-30 | 2024-04-30 | 哈尔滨圣泰生物制药有限公司 | Desloratadine oral preparation and preparation method thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783465A (en) * | 1984-04-09 | 1988-11-08 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
| JPH09502201A (en) * | 1993-09-07 | 1997-03-04 | ザ、プロクター、エンド、ギャンブル、カンパニー | Composition containing amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of decongestant, expectorant, antihistamine and antitussive agent |
| CA2268546A1 (en) * | 1996-10-31 | 1998-05-07 | Schering Corporation | Composition, for the treatment of asthma, containing loratadine and a decongestant |
| US6132758A (en) * | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
| US6051585A (en) * | 1998-12-07 | 2000-04-18 | Weinstein; Robert E. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
| CA2405238C (en) * | 2000-04-14 | 2014-03-18 | J-Med Pharmaceuticals, Inc. | Single-dose antihistamine/decongestant formulations for treating rhinitis |
-
2001
- 2001-05-22 WO PCT/US2001/016570 patent/WO2001089527A2/en not_active Ceased
- 2001-05-22 PA PA20018517201A patent/PA8517201A1/en unknown
- 2001-05-22 BR BR0111018-7A patent/BR0111018A/en not_active Application Discontinuation
- 2001-05-22 AU AU2001264806A patent/AU2001264806A1/en not_active Withdrawn
- 2001-05-22 PE PE2001000462A patent/PE20020055A1/en not_active Application Discontinuation
-
2002
- 2002-10-31 CR CR6804A patent/CR6804A/en not_active Application Discontinuation
- 2002-11-22 EC EC2002004356A patent/ECSP024356A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001089527A3 (en) | 2003-10-16 |
| WO2001089527A2 (en) | 2001-11-29 |
| CR6804A (en) | 2008-10-29 |
| ECSP024356A (en) | 2003-03-31 |
| PA8517201A1 (en) | 2002-08-26 |
| AU2001264806A1 (en) | 2001-12-03 |
| BR0111018A (en) | 2004-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4600739A1 (en) | ALENDRONATE BASED ORAL LIQUID FORMULATIONS | |
| ES2194732T3 (en) | ORAL PHARMACEUTICAL COMPOSITIONS OF CONTROLLED LIBERATION OF MESALAZINE. | |
| PE20010053A1 (en) | AMOXICILLIN AND POTASSIUM CLAVULANATE FORMULATION | |
| AR037490A1 (en) | SOLID PHARMACEUTICAL COMPOSITIONS, PROCESS FOR PREPARATION, KIT FOR THE TREATMENT OF OBESITY AND USE OF SUCH COMPOSITIONS IN THE DEVELOPMENT OF MEDICINES | |
| AR018109A1 (en) | ADMINISTRABLE GALENIC FORMULATION BY ORAL ROUTE THAT ALLOWS AN IMPROVED ABSORPTION OF ACTIVE PRINCIPLES, USE OF AN ABSORPTION MAJORATING AGENT TO PREPARE AN ADMINISTRABLE DOSAGE METHOD BY ORAL ROUTE AND PROCEDURE TO PREPARE THE GINAL FORMULA | |
| ES2193726T3 (en) | MEDICINAL AEROSOL FORMULATIONS. | |
| ES2176684T3 (en) | NEW ASSOCIATIONS OF ACTIVE PRINCIPLES CONTAINING CLOPIDOGREL AND AN ANTHROMBOTIC. | |
| ES2181473T3 (en) | STABLE LIQUID FORMULATIONS OF BOTULINIC TOXIN. | |
| PA8509001A1 (en) | DOSAGE FORM OF DRUGS DRIVEN BY A HYDROGEL | |
| NO20011471D0 (en) | New oral sustained release formulations | |
| BR9611523A (en) | Administration means for analgesic, anti-inflammatory and antipyretic drugs containing nitrous oxide and pharmaceutical compositions containing such means and drugs. | |
| ES2197792B1 (en) | PHARMACEUTICAL FORMULATIONS CONTAINING INTRANASAL MORPHINE. | |
| BR9912694A (en) | Compound to prepare pulmonary administration medication | |
| BR9909266A (en) | Effervescent formulations | |
| AR035034A1 (en) | LIQUID PHARMACEUTICAL COMPOSITION | |
| PE88699A1 (en) | SERTRALINE SUSTAINED RELEASE DOSAGE FORMS | |
| ES2193515T3 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A TRICYCLE COMPOUND WITH BETTER STABILITY, ABSORTIVITY AND IRRITATIVE POTENTIAL LESSON. | |
| ITMI20021392A1 (en) | PHARMACEUTICAL FORMS FOR THE ORAL ADMINISTRATION OF LIQUID DRUGS AT AMBIENT TEMPERATURE EQUIPPED WITH BETTER BIOAVAILABILITY | |
| ES2110212T3 (en) | EFFERVESCENT PHARMACEUTICAL COMPOSITION CONTAINING IBUPROPHEN AND ITS PREPARATION PROCEDURE. | |
| BR9913135A (en) | Oral formulation | |
| AR027554A1 (en) | NEW ADMINSTRATION SYSTEM OF SELF-DRESSING PHARMACOS | |
| PE20030545A1 (en) | RIBAVIRIN SYRUP FORMULATIONS | |
| PE20020055A1 (en) | STABLE LIQUID AND SOLID FORMULATIONS INCLUDING A NON-SEDATING ANTIHISTAMINE AND A NASAL DECONGESTANT | |
| GT199800196A (en) | COMBINATIONS OF STATIN-CARBOXYALKYL ETHER. | |
| ES2142430T3 (en) | PHARMACEUTICAL COMPOUNDS IN THE FORM OF GEL CONTAINING SALTS OF CHONDROITIN SULPHATE SUITABLE FOR ORAL ADMINISTRATION. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |